Clinical outcomes of CARTO FINDER and CFAE (ICL mode) ablation after pulmonary vein isolation for persistent atrial fibrillation

Clinical outcomes of CARTO FINDER and CFAE (ICL mode) ablation after pulmonary vein isolation for persistent atrial fibrillation - Clinical outcomes of CARTO FINDER and CFAE (ICL mode) ablation after pulmonary vein isolation for persistent atrial fibrillation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046550

Enrollment

Registered

2022-01-05

Start date

2022-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

persistent atrial fibrillation

Interventions

CARTOFINDER+CFAE(ICL mode)ablation Pulmonary vein isolation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients with persistent atrial fibrillation during hospital visits who relapsed after 1st ablation 2 Patients who underwent only expanded pulmonary vein isolation in 1st ablation 3 Patients who are indicated for catheter ablation. (Japanese Circulation Society Arrhythmia Drug Treatment Guidelines (Revised 2018) 4 Patients whose age at the time of obtaining consent is 20 to 85 years old 5 Patients who can consent by themselves

Exclusion criteria

Exclusion criteria: 1 Patients who have difficulty in restoring sinus rhythm by cardioversion 2 Patients who do not agree to be the target of this case 3 Patients with persistent atrial fibrillation 4 Other patients who are not qualified by the attending physician

Design outcomes

Primary

Measure	Time frame
2) Total number of PACs PAC short run AT(1,3,6,12 months after surgery) 3) Change in resting heart rate from baseline (1,3,6,12 months after surgery) 4) Amount of change from baseline in the following biochemical tests (3,6,12 months after surgery) Triglyceride, LDL / HDL cholesterol, fatty acid 4 fraction, hemoglobin, hematocrit, cystatin C, renin, aldosterone, Brain natriuretic peptide, Atrial natriuretic peptide, NT-pro BNP 5) Amount of change from baseline in the following echocardiographic findings (3,12 months after surgery) Left ventricular ejection fraction (LVEF), presence or absence of MR (none, mild, moderate, severe), tricuspid regurgitation pressure gradient (none, mild, moderate, severe), left ventricular end diastolic diameter, left ventricular end systole diameter, Left ventricle diameter	—

Measure

Time frame

2) Total number of PACs PAC short run AT(1,3,6,12 months after surgery) 3) Change in resting heart rate from baseline (1,3,6,12 months after surgery) 4) Amount of change from baseline in the following biochemical tests (3,6,12 months after surgery) Triglyceride, LDL / HDL cholesterol, fatty acid 4 fraction, hemoglobin, hematocrit, cystatin C, renin, aldosterone, Brain natriuretic peptide, Atrial natriuretic peptide, NT-pro BNP 5) Amount of change from baseline in the following echocardiographic findings (3,12 months after surgery) Left ventricular ejection fraction (LVEF), presence or absence of MR (none, mild, moderate, severe), tricuspid regurgitation pressure gradient (none, mild, moderate, severe), left ventricular end diastolic diameter, left ventricular end systole diameter, Left ventricle diameter

—

Secondary

Measure	Time frame
1) Total number of PACs PAC short run. AT(1,3,6,12 months after surgery) 2) Change in resting heart rate from baseline (1,3,6,12 months after surgery) 3) Amount of change from baseline in the following biochemical tests (3,6,12 months after surgery) Triglyceride, LDL / HDL cholesterol, fatty acid 4 fraction, hemoglobin, hematocrit, cystatin C, renin, aldosterone, Brain natriuretic peptide, Atrial natriuretic peptide, NT-pro BNP 4) Amount of change from baseline in the following echocardiographic findings (3,12 months after surgery) Left ventricular ejection fraction (LVEF), presence or absence of MR (none, mild, moderate, severe), tricuspid regurgitation pressure gradient (none, mild, moderate, severe), left ventricular end diastolic diameter, left ventricular end systole diameter, Left ventricle diameter	—

Measure

Time frame

1) Total number of PACs PAC short run. AT(1,3,6,12 months after surgery) 2) Change in resting heart rate from baseline (1,3,6,12 months after surgery) 3) Amount of change from baseline in the following biochemical tests (3,6,12 months after surgery) Triglyceride, LDL / HDL cholesterol, fatty acid 4 fraction, hemoglobin, hematocrit, cystatin C, renin, aldosterone, Brain natriuretic peptide, Atrial natriuretic peptide, NT-pro BNP 4) Amount of change from baseline in the following echocardiographic findings (3,12 months after surgery) Left ventricular ejection fraction (LVEF), presence or absence of MR (none, mild, moderate, severe), tricuspid regurgitation pressure gradient (none, mild, moderate, severe), left ventricular end diastolic diameter, left ventricular end systole diameter, Left ventricle diameter

—

Countries

Japan

Contacts

Public ContactMorio Ono

Showa University Northern Yokohama Hospital Cardiology

morio.ono@gmail.com(+81)45-949-7000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026